TMCnet News
IONETIX announces appointment of Douglas Boothe to Board of DirectorsLANSING, Mich., March 26, 2024 /PRNewswire/ -- IONETIX, a leading cyclotron technology and isotope manufacturing company, is pleased to announce the appointment of Douglas Boothe to its Board of Directors. Mr. Boothe currently serves as CEO at Edenbridge Pharmaceuticals and brings over 30 years of leadership skills and proven business results in pharmaceutical sales, marketing, operations, business development, and regulatory to IONETIX. "Doug's deep pharmaceutical expertise and proven track record aligns well with our growth strategy and will help guide IONETIX at this pivotal time for the company," said Kevin Cameron, Chairman of IONETIX. Boothe noted, "I am excited to join IONETIX at such a dynamic time for both the company and the radiopharmaceutical space broadly. I look forward to helping the team through what promises to be a period of significant growth." About Mr. Boothe: About IONETIX: IONETIX is a US-based cyclotron and technology company founded in 2009. IONETIX offers turnkey diagnostic radiopharmaceutical services domestically, cyclotron equipment and installation services globally, and is actively developing Targeted Alpha Therapy (TAT) isotope production and TAT pharmaceutical manufacturing services. Contact: Pete Burke • [email protected] • 614-623-1383 View original content to download multimedia:https://www.prnewswire.com/news-releases/ionetix-announces-appointment-of-douglas-boothe-to-board-of-directors-302097385.html SOURCE IONETIX |